New hope for tough lung cancers: drug combo trial opens
NCT ID NCT07232849
First seen Nov 18, 2025 · Last updated May 15, 2026 · Updated 20 times
Summary
This study tests a new drug called HRS-4508 combined with other cancer treatments for people with advanced non-small cell lung cancer that has stopped responding to standard therapy. About 100 adults aged 18 to 75 will participate. The goal is to find the best dose and see if the combination shrinks tumors and improves survival, while monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
RECRUITINGShanghai, Shanghai Municipality, 200430, China
Contact
-
Zhejiang Tumor Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact
Conditions
Explore the condition pages connected to this study.